MacroGenics Inc at Morgan Stanley Healthcare Conference Transcript
David has been delayed. So I'll be happy to actually comment -- I mean as you know, we have a company that is sort of at a wonderful juncture in its development right now. Just to refresh your memory, we have currently 9 molecules in Phase I to Phase III development. There is a lot of focus these days on margetuximab. As you recall, margetuximab is an Fc-engineered antibody targeted to HER2. It's one of the 2 proprietary platforms that MacroGenics has developed along with our bispecific multispecific DART program.
Just to give you a little bit of sense of where we are on margetuximab. As you recall, in February of this year, we announced a positive Phase III data in a trial called SOPHIA, where we are comparing the activity in late-stage third-line metastatic breast cancer in patients who have been experienced with HERCEPTIN, Perjeta and Kadcyla. And we did a comparison against HERCEPTIN in combination with chemotherapy. We had a successful readout on the first sequential endpoint, which was PFS, where we saw an improvement in intent
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
